EurekAlert! -
19 Aug 2016 06:00
(University of California - San Diego) Rheumatoid arthritis patients taking medications that inhibit interleukin-1beta, a molecule that stimulates the immune system, are 300 times more likely to experience invasive Group A Streptococcal infections than patients not on the drug, according to University of California San Diego School of Medicine researchers. Their study, published Aug. 19 in Science Immunology, also uncovers a critical new role for IL-1beta as the body's independent early warning ...
Share this Article